FOLH1 and prostate cancer: While no consensus on the SUVMax cut-off has been established to predict malignancy or clinically significant prostate cancer (csPCa), studies have reported a notable correlation between the percentage of IHC expression of PSMA in the PCa cell membranes and a higher malignancy grade [22].